))
Advancements in Heart Failure Clinical Research
Manage episode 425413603 series 2849626
Contenuto fornito da BEaTS Research Radio. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da BEaTS Research Radio o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Nicole Chu from the University of Ottawa speaks with Dr. Javed Butler. Dr. Javed Butler, MD, MPH, MBA, is the President of the Baylor Scott and White Research Institute, and Senior Vice President and Maxwell A. and Gayle H. Clampitt Endowed Chair at the Baylor Scott and White Health in Dallas, Texas. He is also the Distinguished Professor of Medicine at the University of Mississippi in Jackson, Mississippi. In this episode, Dr. Butler shares with us the major findings from the recent EMPACT-MI clinical trial and his perspective on the future of heart failure therapies. The EMPACT-MI trial investigated whether a medicine called empagliflozin, a SGLT2 inhibitor, helps to lower the risk of heart failure and death in people had experienced a heart attack (myocardial infarction).
Learn more about the EMPACT-MI clinical trial https://www.nejm.org/doi/full/10.1056/NEJMoa2206286
31 episodi
Condividi
